Success Metrics

Clinical Success Rate
84.8%

Based on 379 completed trials

Completion Rate
85%(379/447)
Active Trials
73(11%)
Results Posted
46%(176 trials)
Terminated
68(10%)

Phase Distribution

Ph phase_4
191
28%
Ph phase_1
88
13%
Ph early_phase_1
32
5%
Ph not_applicable
147
22%
Ph phase_2
131
19%
Ph phase_3
57
8%

Phase Distribution

120

Early Stage

131

Mid Stage

248

Late Stage

Phase Distribution646 total trials
Early Phase 1First-in-human
32(5.0%)
Phase 1Safety & dosage
88(13.6%)
Phase 2Efficacy & side effects
131(20.3%)
Phase 3Large-scale testing
57(8.8%)
Phase 4Post-market surveillance
191(29.6%)
N/ANon-phased studies
147(22.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.5%

379 of 489 finished

Non-Completion Rate

22.5%

110 ended early

Currently Active

73

trials recruiting

Total Trials

679

all time

Status Distribution
Active(90)
Completed(379)
Terminated(110)
Other(100)

Detailed Status

Completed379
unknown93
Terminated68
Recruiting59
Withdrawn42
Not yet recruiting14

Development Timeline

Analytics

Development Status

Total Trials
679
Active
73
Success Rate
84.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 132 (5.0%)
Phase 188 (13.6%)
Phase 2131 (20.3%)
Phase 357 (8.8%)
Phase 4191 (29.6%)
N/A147 (22.8%)

Trials by Status

not_yet_recruiting142%
withdrawn426%
suspended71%
active_not_recruiting142%
unknown9314%
recruiting599%
enrolling_by_invitation30%
completed37956%
terminated6810%

Recent Activity

Clinical Trials (679)

Showing 20 of 679 trialsScroll for more
NCT07640243Not Applicable

Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery

Recruiting
NCT05306899Phase 3

Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

Recruiting
NCT02734602Not Applicable

Imaging SV2A in Mood Disorders

Active Not Recruiting
NCT03065335Phase 1

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Recruiting
NCT06538285Phase 2

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

Active Not Recruiting
NCT06179485

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

Enrolling By Invitation
NCT05597878Phase 2

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Terminated
NCT05378100Phase 2

Ketamine for Multiple Sclerosis Fatigue

Active Not Recruiting
NCT05327699Early Phase 1

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Recruiting
NCT05625555Phase 3

Predictors of Intravenous Ketamine Response in TRD

Active Not Recruiting
NCT07294092Early Phase 1

Ketamine and Propofol NeuroImaging

Recruiting
NCT06853041Phase 4

ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects

Completed
NCT07182032Phase 4

Ketamine in Central Sensitization

Withdrawn
NCT05086250Early Phase 1

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

Recruiting
NCT01892189Phase 1

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Completed
NCT06490731Phase 1

Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients

Recruiting
NCT05915013Phase 1

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Recruiting
NCT05786066Phase 2

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Recruiting
NCT04291521

Prospective Study of Induction Medications Used in the Trauma RSI

Withdrawn
NCT02122562Phase 2

Ketamine Alcohol (in Treatment-Resistant Depression)

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
679